MiGenTra Egypt

MiGenTra Egypt is the first R&D and manufacturing biopharmaceutical facility in Egypt, Africa, and the Middle East.

The company specializes in the development and manufacturing of therapeutic recombinant proteins with a primary focus on the areas of liver disease, thrombosis and haemostasis, infertility, oncology, as well as rheumatoid arthritis.

The company’s first and foremost goal is to provide patients with highly innovative and affordable genetically engineered recombinant drugs with the highest standard of quality.

MiGenTra Egypt, as a subsidiary of Minapharm, carries out the process and clinical development of biopharmaceutical pipeline candidates and produces protein API which is further formulated and manufactured into finished product by Minapharm, as well as registered and marketed/ commercialized.